At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories. That it depends thereby less on large names, but on the future potential and whether the market also recognizes these perspectives, was one of its first learnings at the stock exchange.
On these pages, Nico examines current events at listed companies and takes a closer look at companies that are traded under the radar of the market, in addition to well-known securities.
In order to be able to take advantage of speculative opportunities on the stock exchange, Nico not only focuses on a balanced asset allocation of defensive and opportunity-oriented securities, but also on an intact risk management. "In addition to position size and entry in several tranches, investors should also develop a sense of timing and get to know a stock better before investing," says the columnist.
Kommentare von Nico Popp
Kommentar von Nico Popp vom 13.04.2023 | 07:00
Defence Therapeutics revs up mRNA vaccines
A few days ago, the biotech company Defence Therapeutics announced the launch of its mRNA vaccine program against cancer. The assumption behind this: mRNA vaccines become more effective when combined with Defence Therapeutics' patented drug enhancer Accum™. The Company now wants to test a specially produced mRNA vaccine in its pure form against the combination of mRNA vaccine and Accum™ in a clinical trial. Looking more closely at the challenges of mRNA vaccines, Accum™ could also make other projects more effective and become a sought-after adjuvant technology around mRNA. Find out what is behind it and how great the potential could be.
Zum Kommentar
Kommentar von Nico Popp vom 11.04.2023 | 07:30
Defence Therapeutics launches mRNA vaccine program against cancer
Yesterday after the close of trading in Canada, Defence Therapeutics announced the launch of its mRNA vaccine program against cancer. This will involve combining mRNA molecules with Accum™ technology and will be followed by the comparison of the mRNA-Accum™ combination with naked mRNA. The background to the scientific investigation is that mRNA injected into the body is often destroyed as part of immune responses and other processes. Defence Therapeutics believes these processes are absent when combined with Defence's patented Accum™ technology. We look at what the latest news means, where Defence stands right now and what questions investors still need to be answered concerning the Defence Therapeutics share.
Zum Kommentar
Kommentar von Nico Popp vom 15.03.2023 | 07:30
Stock news: Defence Therapeutics to cooperate with French state-owned Orano group
When corporations want to collaborate with biotech innovators, it is like an accolade - big companies usually take longer to commit. Defence Therapeutics' most recently announced collaboration with French state-owned Orano raises eyebrows for several reasons. Find out what the cooperation in the field of nuclear medicine is all about and what potential could arise from the collaboration.
Zum Kommentar
Kommentar von Nico Popp vom 28.02.2023 | 07:11
Stock news: Defence Therapeutics with 6 potential billion-dollar blockbusters
Defence Therapeutics' pipeline offers market potential in the range of several hundred billion USD. We present the six most important projects and explain why 2023 will be crunch time for Defence Therapeutics - the decisive phase for the Company and its shareholders is just around the corner. As Defence continues to write its success stories, the multifaceted Canadian company could soon be wooed by pharmaceutical giants - the first collaborations have already been signed.
Zum Kommentar
Kommentar von Nico Popp vom 22.02.2023 | 05:40
Stock news: Defence Therapeutics - Big step towards FDA approval
The renowned City of Hope Clinic in the greater Los Angeles area wants nothing less than to lead the revolution in the fight against cancer. Here, where globally acclaimed breakthroughs against blood cancer and diabetes were achieved in the 1970s, the biotech company Defence Therapeutics now wants to clear important hurdles in the approval process of the US Food and Drug Administration (FDA). Here is what the collaboration is all about and what it could mean for the young biotech company.
Zum Kommentar
Kommentar von Nico Popp vom 06.02.2023 | 05:00
Defence Therapeutics - Science community sees potential for "treating a broad range of cancers"
Scientific findings gain significance when validated and discussed by independent researchers. Defence Therapeutics' technology recently received funding and expert endorsement from Canadian biotech funder CQDM, which is funded by numerous industry multinationals, among others. We look at what the collaboration could mean for Defence Therapeutics, why nasal spray as chemotherapy is increasingly likely, and why Defence's technology portfolio fits the bill right now in what analysts expect to be a wave of acquisitions in the biotech sector.
Zum Kommentar
Kommentar von Nico Popp vom 30.01.2023 | 06:00
Stock news: Biotech hopeful Defence Therapeutics faces New York's financial elite
In January, a healthcare conference hosted by JP Morgan kissed the entire biotech industry awake. Another industry meeting is now scheduled for February in New York. Defence Therapeutics will be giving two presentations there to present itself to colleagues and investors. The Canadians will be presenting a flexible, patented platform technology and a whole series of projects that are about to enter Phase I trials. An mRNA vaccine candidate against skin cancer recently convinced with a cure rate of 60% in animals. We shed light on the Company and the share.
Zum Kommentar
Kommentar von Nico Popp vom 23.01.2023 | 06:00
Stock news: Defence Therapeutics brings back momentum from 2020
The years 2020 and 2021 represent rapid share price gains. In recent trading days, the Defence Therapeutics share has built up momentum reminiscent of the stock market boom of that time. At the same time, things are moving forward operationally. In the coming weeks and months, the Company plans to move several projects related to the fight against cancer into Phase 1 trials. According to market researchers, the market potential for all projects could reach USD 100 billion by 2030. In this report, we learn what is at stake now, what announcements are making prices rise and why a takeover bid is possible at any time.
Zum Kommentar
Kommentar von Nico Popp vom 16.01.2023 | 06:00
Stock News: Defence Therapeutics - Groundbreaking results ahead
Cancer changes everything. Effective remedies against the scourge of our time would be a revolution. Defence Therapeutics is working to turn hope into fact: In the coming weeks, vaccines against cancer are to be combined with Accum, a drug enhancer patented by Defence, and then clinically tested. For the Company, this could mean a breakthrough at a time when the big players in the industry are paying close attention to innovative biotechs with a platform approach. With the help of facts and figures, we outline where Defence Therapeutics currently stands, which projects could ultimately result in a convincing overall picture and why the share has excellent prospects.
Zum Kommentar
Kommentar von Nico Popp vom 25.10.2022 | 06:01
Stock news: XPhyto pushes into lucrative markets with two projects
Opportunities arise for companies when copycat drugs are just as good as the original. The Canadian company XPhyto has taken a big step toward market readiness in the fight against Parkinson's disease. Over the next five minutes, we briefly explain what is important now and how great the opportunities are. We also show how XPhyto is helping to counter the opioid wave in the USA and what imagination lies in the little-noticed business field of psychedelics.
Zum Kommentar